Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0000909661 XXXXXXXX LIVE 1 Ordinary Shares, nominal value GBP 0.002 per share (the "Ordinary Shares") 06/24/2026 0001847903 152309100 Centessa Pharmaceuticals plc 3rd Floor, 1 Ashley Road Altrincham Cheshire X0 WA14 2DT Hannah E. Dunn (415) 421-2132 Farallon Capital Management, L.L.C. One Maritime Plaza, Suite 2100 San Francisco CA 94111 0000909661 N FARALLON CAPITAL MANAGEMENT, L.L.C. b AF DE 0 0 0 0 0 0 IA OO Y Dapice Joshua J. b AF X1 0 0 0 0 0 0 IN Y Dreyfuss, Philip D. b AF X1 0 0 0 0 0 0 IN Y Dunn Hannah E. b AF X1 0 0 0 0 0 0 IN Y Gehani, Varun N. b AF X1 0 0 0 0 0 0 IN Y Giauque, Nicolas b AF I0 0 0 0 0 0 0 IN Y Husen, Avner A. b AF X1 0 0 0 0 0 0 IN Y Kim, David T. b AF X1 0 0 0 0 0 0 IN Y Linn, Michael G. b AF X1 0 0 0 0 0 0 IN Y Luo Patrick (Cheng) b AF F4 0 0 0 0 0 0 IN Y Roberts, Jr., Thomas G. b AF X1 0 0 0 0 0 0 IN Y Saito Edric C. b AF X1 0 0 0 0 0 0 IN Y Short Daniel S. b AF X1 0 0 0 0 0 0 IN Y Spokes, Andrew J. M. b AF X0 0 0 0 0 0 0 IN Y Warren, John R. b AF X1 0 0 0 0 0 0 IN Y Wehrly, Mark C. b AF X1 0 0 0 0 0 0 IN Ordinary Shares, nominal value GBP 0.002 per share (the "Ordinary Shares") Centessa Pharmaceuticals plc 3rd Floor, 1 Ashley Road Altrincham Cheshire X0 WA14 2DT This Amendment No. 1 to Schedule 13D (this "Amendment") hereby amends and restates Item 5(a) in its entirety, to read as follows: "On June 24, 2026, the Reporting Persons disposed of all previously reported Ordinary Shares in connection with the closing of the acquisition by Eli Lilly and Company, through its wholly owned subsidiary LDH XV Corporation, of all outstanding Ordinary Shares of the Issuer, as described by the Issuer in its Form 8-K filed with the Securities and Exchange Commission on June 24, 2026." This Amendment hereby amends and restates Item 5(c) in its entirety, to read as follows: "The disclosure set forth in Item 5(a) above is hereby incorporated by reference in this Item 5(c)." FARALLON CAPITAL MANAGEMENT, L.L.C. /s/ Hannah E. Dunn Hannah E. Dunn, Managing Member 06/26/2026 Dapice Joshua J. /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact 06/26/2026 Dreyfuss, Philip D. /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact 06/26/2026 Dunn Hannah E. /s/ Hannah E. Dunn Hannah E. Dunn 06/26/2026 Gehani, Varun N. /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact 06/26/2026 Giauque, Nicolas /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact 06/26/2026 Husen, Avner A. /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact 06/26/2026 Kim, David T. /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact 06/26/2026 Linn, Michael G. /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact 06/26/2026 Luo Patrick (Cheng) /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact 06/26/2026 Roberts, Jr., Thomas G. /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact 06/26/2026 Saito Edric C. /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact 06/26/2026 Short Daniel S. /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact 06/26/2026 Spokes, Andrew J. M. /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact 06/26/2026 Warren, John R. /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact 06/26/2026 Wehrly, Mark C. /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact 06/26/2026